MX2010008750A - Nuevos macrolidos y su uso. - Google Patents
Nuevos macrolidos y su uso.Info
- Publication number
- MX2010008750A MX2010008750A MX2010008750A MX2010008750A MX2010008750A MX 2010008750 A MX2010008750 A MX 2010008750A MX 2010008750 A MX2010008750 A MX 2010008750A MX 2010008750 A MX2010008750 A MX 2010008750A MX 2010008750 A MX2010008750 A MX 2010008750A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory
- compounds
- prevention
- treatment
- relates
- Prior art date
Links
- 239000003120 macrolide antibiotic agent Substances 0.000 title abstract 3
- 229940041033 macrolides Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a compuestos macrólidos de la fórmula (I), (ver fórmula (I)) al uso de estos compuestos como medicamentos, en particular para el tratamiento o prevención de enfermedades inflamatorias y alérgicas, a composiciones farmacéuticas que contienen estos compuestos y a procedimientos para su preparación. La invención se refiere en particular a compuestos macrólidos con actividad anti-inflamatoria mediada principalmente a través de la inhibición de fosfodiesterasa 4 (PDE4) lo cual los hace útiles para el tratamiento y/o prevención de enfermedades inflamatorias y alérgicas tales como enfermedad pulmonar obstructiva crónica (COPD), asma, artritis reumatoide, dermatitis atópica o enfermedad inflamatoria del intestino o enfermedades proliferativas tales como cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08101438 | 2008-02-08 | ||
| PCT/EP2009/051441 WO2009106419A1 (en) | 2008-02-08 | 2009-02-09 | New macrolides and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010008750A true MX2010008750A (es) | 2010-08-31 |
Family
ID=40784129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010008750A MX2010008750A (es) | 2008-02-08 | 2009-02-09 | Nuevos macrolidos y su uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8410065B2 (es) |
| EP (1) | EP2245038B1 (es) |
| JP (1) | JP5651019B2 (es) |
| KR (1) | KR101617897B1 (es) |
| CN (1) | CN101939327B (es) |
| AU (1) | AU2009218671B2 (es) |
| BR (1) | BRPI0908343A2 (es) |
| CA (1) | CA2713776C (es) |
| MX (1) | MX2010008750A (es) |
| WO (1) | WO2009106419A1 (es) |
| ZA (1) | ZA201005482B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2714389C (en) * | 2008-02-08 | 2016-10-18 | Basilea Pharmaceutica Ag | Macrolides and uses of macrolides |
| WO2013008928A1 (ja) * | 2011-07-14 | 2013-01-17 | 大正製薬株式会社 | マクロライド誘導体 |
| ES2607638T3 (es) * | 2012-12-31 | 2017-04-03 | Basilea Pharmaceutica Ag | Macrólidos seleccionados con actividad inhibidora de PDE4 |
| CN103172686B (zh) * | 2013-04-08 | 2015-06-24 | 山东大学 | 克拉霉素-n-氧化物的制备方法 |
| CN103215238B (zh) * | 2013-04-12 | 2014-09-03 | 国家海洋局第二海洋研究所 | 一种海洋细菌酯酶及其制备方法与应用 |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| PT4118091T (pt) | 2020-03-12 | 2025-08-20 | Zoetis Services Llc | Ureia azalídeos imunomoduladores |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0922050T3 (da) | 1996-05-07 | 2003-11-24 | Abbott Lab | 3-Descladinose-2,3-anhydroerythromycin-derivater |
| ES2313975T3 (es) | 2000-08-22 | 2009-03-16 | Basilea Pharmaceutica Ag | Nuevos macrolidos con actividad antibacteriana. |
| AU2002316550A1 (en) | 2001-07-03 | 2003-01-21 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| EP1430068A1 (en) | 2001-09-17 | 2004-06-23 | Ortho-Mcneil Pharmaceutical, Inc. | 6-o-carbamate-11,12-lacto-ketolide antimicrobials |
| GB0127349D0 (en) | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| US6995143B2 (en) * | 2002-02-28 | 2006-02-07 | Basilea Pharmaceutica Ag | Macrolides with antibacterial activity |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US6727229B2 (en) * | 2002-08-19 | 2004-04-27 | Enanta Pharmaceuticals, Inc. | 11,12-substituted lactone ketolide derivatives having antibacterial activity |
| US6720308B1 (en) * | 2002-11-07 | 2004-04-13 | Enanta Pharmaceuticals, Inc. | Anhydrolide derivatives having antibacterial activity |
| AU2003304705A1 (en) | 2003-12-24 | 2005-08-03 | Enanta Pharmaceuticals, Inc. | 11-csubsituted erythromycin derivatives |
| AU2006205828A1 (en) * | 2005-01-12 | 2006-07-20 | Alpharma Aps | Erythromycin derivatives as antibacterial agents |
| CN101115764B (zh) * | 2005-02-09 | 2012-09-26 | 巴斯利尔药物股份公司 | 大环内酯类化合物 |
| JP5112079B2 (ja) * | 2005-02-09 | 2013-01-09 | バジリア ファルマスーチカ アーゲー | 新規なマクロライド |
| EP1957085A2 (en) | 2005-11-08 | 2008-08-20 | Ranbaxy Laboratories, Ltd. | Macrolides as anti-inflammatory agents |
| JP5126685B2 (ja) * | 2006-05-01 | 2013-01-23 | 大正製薬株式会社 | マクロライド誘導体 |
| WO2008017696A1 (en) * | 2006-08-09 | 2008-02-14 | Basilea Pharmaceutica Ag | New macrolides useful against inflammatory and allergic disseases |
-
2009
- 2009-02-09 US US12/864,921 patent/US8410065B2/en not_active Expired - Fee Related
- 2009-02-09 JP JP2010545493A patent/JP5651019B2/ja not_active Expired - Fee Related
- 2009-02-09 KR KR1020107019813A patent/KR101617897B1/ko not_active Expired - Fee Related
- 2009-02-09 CN CN200980104218.9A patent/CN101939327B/zh not_active Expired - Fee Related
- 2009-02-09 MX MX2010008750A patent/MX2010008750A/es active IP Right Grant
- 2009-02-09 WO PCT/EP2009/051441 patent/WO2009106419A1/en not_active Ceased
- 2009-02-09 BR BRPI0908343-0A patent/BRPI0908343A2/pt not_active IP Right Cessation
- 2009-02-09 EP EP09715960.2A patent/EP2245038B1/en active Active
- 2009-02-09 CA CA2713776A patent/CA2713776C/en not_active Expired - Fee Related
- 2009-02-09 AU AU2009218671A patent/AU2009218671B2/en not_active Ceased
-
2010
- 2010-07-30 ZA ZA2010/05482A patent/ZA201005482B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110053876A1 (en) | 2011-03-03 |
| BRPI0908343A2 (pt) | 2020-08-18 |
| AU2009218671A1 (en) | 2009-09-03 |
| AU2009218671B2 (en) | 2013-11-14 |
| EP2245038A1 (en) | 2010-11-03 |
| JP5651019B2 (ja) | 2015-01-07 |
| KR20100115363A (ko) | 2010-10-27 |
| CN101939327A (zh) | 2011-01-05 |
| JP2011511043A (ja) | 2011-04-07 |
| EP2245038B1 (en) | 2018-11-07 |
| KR101617897B1 (ko) | 2016-05-03 |
| CA2713776C (en) | 2018-06-05 |
| US8410065B2 (en) | 2013-04-02 |
| CA2713776A1 (en) | 2009-09-03 |
| CN101939327B (zh) | 2015-03-11 |
| ZA201005482B (en) | 2011-04-28 |
| WO2009106419A1 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010008750A (es) | Nuevos macrolidos y su uso. | |
| WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
| UA88472C2 (en) | Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors | |
| WO2013163190A8 (en) | Dna-pk inhibitors | |
| SG155943A1 (en) | Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors | |
| CL2008003056A1 (es) | Compuestos derivados de 3-fenil-imidazo[1,2-a]piridinas; composicion farmaceutica; proceso para su preparacion, util como inhibidores de alk-5 o alk-4 en el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, cancer, enfermedades musculares, trastornos esqueleticos | |
| MX2009006540A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides. | |
| WO2010142766A3 (en) | Pyrimidine derivatives as zap-70 inhibitors | |
| WO2010014253A3 (en) | Ant4 inhibitor compounds and methods of use thereof | |
| UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
| WO2008152093A3 (en) | Diaminopyrimidines as modulators of the ep2 receptor | |
| WO2008086462A3 (en) | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | |
| WO2007005668A3 (en) | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer | |
| MX2016006330A (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| GEP20186885B (en) | Novel compounds | |
| WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| WO2009030952A3 (en) | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| WO2007114848A3 (en) | Chemical compounds | |
| MX336332B (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
| WO2008035315A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| WO2011006803A8 (en) | 3-0x0-2, 3, -dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition | |
| WO2010009377A3 (en) | Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases | |
| WO2008152094A3 (en) | Substituted acetamides as modulators of the ep2 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |